FY2019 · ended Dec 31, 2019 · Revenue $1.58M, -5.3% YoY · Filed Mar 1, 2021
Q/C Technologies, Inc. (QCLS) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. Free cash flow was -$10.8 million. As of Jun 30, 2026 it held $11.0 million in cash and investments and $371,171 in total debt.
Revenue (TTM)
$862,026
-54.9% vs year-ago TTM
Net income (TTM)
$-4.25M
+50.7% vs year-ago TTM
Operating cash flow (TTM)
$-9.47M
-2.3% vs year-ago TTM
Free cash flow
$-10.82M
-26.2% vs prior year
EPS
$-8.66
+99.2% vs prior year
Dividend per share
None
Shares outstanding
7.85M
+0.0% vs prior year
Net cash
$10.62M
as of Jun 30, 2026
Operating margin
-439.3%
FY 2020
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- QCLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1321834
- Former names
- Q/C TECHNOLOGIES, INC. (until Oct 2, 2026); TNF Pharmaceuticals, Inc. (until Sep 10, 2025); MyMD Pharmaceuticals, Inc. (until Jul 1, 2024); Akers Biosciences, Inc. (until Apr 16, 2021); Akers Biosciences Inc (until Apr 11, 2017)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$9.8M | -$10.2M | -$17.1M | -$15.3M | -$28.8M |
| Net income | -$11.6M | -$23.4M | -$4.0M | -$15.2M | -$29.9M |
| Diluted EPS | -$8.66 | -$1,080.87 | -$5.33 | — | — |
| Operating cash flow | -$9.1M | -$9.0M | -$13.0M | -$12.3M | -$19.5M |
| Free cash flow | -$10.8M | — | — | — | — |
| Total assets | $41.2M | $21.4M | $17.9M | $17.5M | $24.8M |
| Total liabilities | $16.4M | $6.7M | $5.1M | $2.8M | $1.2M |
| Stockholders' equity | $21.8M | $9.8M | $12.4M | $14.7M | $23.6M |
| Cash and investments | $15.8M | $8.5M | $6.4M | $6.3M | $13.1M |
| Total debt | — | $10,579 | $48,870 | $141,721 | $149,151 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
Sep 18, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Agreement ended, Officer or director change
|
Sep 11, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Agreement ended, Other events
|
Jul 2, 2026 | Jun 26, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 29, 2026 | Dec 31, 2025 |
All 604 Q/C Technologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.